Drugs / DC6001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07417566 | Jan → Dec 2026 expected | Stargardt disease | Heronova Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC6001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417566 ↗ |
| Route | Oral | “Participants received single dose of DC6001 orally. Dose levels are 2 mg, 5 mg, 10 mg, 20 mg and 40 mg.” NCT07417566 ↗ |